Company Overview and News


Add 500680
to your dashboard

Headline News

Pfizer (PFE) a Hold on Poor Earnings Visibility

13h investorplace
The current recommendation of Hold for Pfizer Inc (NYSE:PFE) has been derived by using Louis Navellier's methodology for investing and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for the last month. (16-0)

Exelixis, Ipsen Report Positive Results on Lead Cancer Drug

18h zacks
Exelixis, Inc. (EXEL - Free Report) and Ipsen announced positive detailed results from the pivotal phase III CELESTIAL study of Cabometyx (cabozantinib)  demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma (HCC). (69-0)

Pfizer Limited - Results

2018-01-15 nseindia
(16-0)

3 Reasons Dividend-Monster Pfizer Inc. Could Explode Higher

2018-01-12 investorplace
Pfizer Inc. (NYSE:PFE) has been rather quietly churning higher. Over the last six months, Pfizer stock is up nearly 10% and it hit new highs in December. (86-0)

Where’s Mine? Workers Wonder If Trump Tax Cut Will Trickle Down - Bloomberg

2018-01-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (103-0)

Big Pharma Tax Cut Fruits Pretty Dull, Actually - Bloomberg

2018-01-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (16-0)

Valeant Pharmaceuticals Intl Inc Stock Is Worth the Risk

2018-01-11 investorplace
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has begun a turnaround. The Laval, Canada-based drug manufacturer is on a growth path again after VRX stock came crashing from lofty highs. A new CEO now works to drive profits and reduce a heavy debt burden. (190-0)

The 5 Best Dow Jones Stocks to Buy for 2018

2018-01-10 investorplace
Despite all the pundit noise and hate, the Dow Jones Industrial Average is still a wonderful place to find great stocks and big-time dividends. The thirty Dow Jones Stocks are still powerhouses in their respective fields and feature enviable moats, large cash flows, and big-time profits. (290-1)

5 ETFs to Bet on 2018 Dogs of the Dow

2018-01-10 investorplace
Although the ‘Dogs of the Dow’ strategy has a history of outperforming the Dow Jones Industrial Average over the long term, it lagged in 2017, returning just 19% compared with 25% gains for the blue-chip index. Before 2017, the Dogs had generated outsized returns in six of the seven previous years, missing only in 2012. (164-0)

7 Stocks With ‘Tax Cut’ Dividend Increases on Tap

2018-01-10 investorplace
Congress and President Donald Trump passed a historic tax cut late last year, lowering the corporate tax rate from 35% to 21%. This monumental legislation should place hundreds of billions of dollars back in the hands of corporations. But which companies will put these dollars in the hands of investors as dividend increases? (330-0)

UPDATE 1-UK Stocks-Factors to watch on Jan 10

2018-01-10 reuters
Jan 10 (Reuters) - Britain’s FTSE 100 index is seen opening down 4 points on Wednesday, according to financial bookmakers, with futures down 0.07 percent ahead of the cash market open. (23-0)

US pharma executives expect deals to pick up after tax overhaul

2018-01-10 themalaymailonline
Eli Lilly & Co CEO Dave Ricks poses for a picture at the J.P. Morgan Healthcare Conference in San Francisco, California, January 9, 2018. — Reuters pic NEW YORK, Jan 10 — The Trump administration’s tax overhaul should accelerate major acquisitions by drugmakers in 2018 after a slow year for deals in 2017, according to senior executives from some of the largest pharmaceutical manufacturers. (208-1)

GSK CEO looking at Pfizer consumer business, but not a priority

2018-01-10 themalaymailonline
GlaxoSmithKline (GSK) CEO, Emma Walmsley, arrives for a meeting in Downing Street in central London, Britain, October 9, 2017. — Reuters pic NEW YORK, Jan 10 — GlaxoSmithKline’s new chief executive said yesterday that the British drugmaker would have a look at Pfizer Inc’s consumer products business, but would not overpay for the asset. (16-0)

GSK CEO says looking at Pfizer consumer business, but not a priority

2018-01-09 reuters
(Reuters) - GlaxoSmithKline’s (GSK.L) new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc’s (PFE.N) consumer products business, but would not overpay for the asset. (16-0)

10 Dividend Stocks You Can Set and Forget | InvestorPlace

2018-01-09 investorplace
Tired of keeping a close eye on financial news and popping in and out of positions in an effort to get the most out of an increasingly volatile market? (135-1)